Histologic grade is a measure of how much cancer cells resemble the normal, healthy cells of the tissue they came from. A pathologist determines it by examining a tissue sample under a microscope, scoring how organized or disorganized the cells appear. The grade is one of the key pieces of information on a pathology report, helping predict how aggressively a cancer is likely to behave.
How Histologic Grade Works
Normal cells in your body have a predictable shape, size, and arrangement. When cells become cancerous, they can lose some or all of those normal features. Histologic grading captures how far that transformation has gone. The standard system uses four grades:
- Grade I (well-differentiated): Cancer cells still closely resemble the tissue they originated from. They tend to be organized and slower growing.
- Grade II (moderately differentiated): Cells fall somewhere in the middle, sharing some features with normal tissue but showing clear abnormalities.
- Grade III (poorly differentiated): Cells look very different from normal tissue. They’re disorganized under the microscope and typically grow and spread faster.
- Grade IV (undifferentiated or anaplastic): Cells bear no resemblance to the tissue of origin. These cancers tend to be the most aggressive.
In short, the lower the grade, the more “normal” the cells look and the slower the cancer generally grows. Higher grades signal faster growth and a greater likelihood of spreading.
What Pathologists Look For
The grade isn’t a gut impression. Pathologists evaluate specific microscopic features and assign numerical scores to each one. In breast cancer, for example, the widely used Nottingham grading system scores three features: how much the cells still form the tube-like structures normal breast tissue makes, how varied the cell nuclei look in size and shape (called nuclear pleomorphism), and how many cells are actively dividing at the time the sample is taken (the mitotic count). Each feature gets a score from 1 (most normal) to 3 (most abnormal), and the three scores are added together. A total of 3 to 5 equals grade I, 6 to 7 equals grade II, and 8 to 9 equals grade III.
Other cancers have their own grading systems tailored to the biology of that specific tissue. Prostate cancer uses a system built on the Gleason score, where a pathologist identifies the two most common growth patterns in the sample, scores each one, and adds them together (for instance, 3+4=7). Brain tumors follow a separate World Health Organization system that grades tumors within each tumor type rather than across all brain cancers as a group. If you see a grade on your pathology report, the system used depends on where the cancer originated.
Grade vs. Stage
These two terms appear on the same reports but measure completely different things. Grade describes what cancer cells look like under a microscope. Stage describes the physical extent of the disease: how large the tumor is and whether it has spread to lymph nodes or other organs. A small, early-stage tumor can still be high grade, meaning it looks aggressive at the cellular level even though it hasn’t spread far yet. Conversely, a large tumor can be low grade. Both pieces of information matter, and doctors use them together, along with genetic features of the tumor, your age, and your overall health, to build a treatment plan.
Why Grade Matters for Treatment
Grade gives doctors a window into how a cancer is likely to behave over time. A low-grade tumor that closely resembles normal tissue is generally slower to grow and spread, which may mean less aggressive treatment is appropriate. A high-grade tumor signals that the cancer is more likely to grow quickly, and treatment plans often reflect that urgency with more intensive approaches.
Grade is rarely the only factor driving treatment decisions. It’s one input alongside stage, the tumor’s molecular and genetic profile, and patient-specific factors. But in certain cancers, grade carries significant weight. In breast cancer, for instance, a grade III result can shift recommendations toward additional therapy even when the tumor is small.
Limitations of Grading
One challenge with histologic grade is that pathologists can only examine the portions of a tumor that are sampled. Large tumors are rarely analyzed in their entirety. Instead, pathologists select representative sections based on standard protocols, operating on the assumption that those sections reflect the whole mass. In reality, different areas of the same tumor can show different grades. This internal variation means a biopsy from one part of the tumor might yield a lower grade than a sample taken from another region. For cancers where grading affects treatment decisions, surgeons and pathologists sometimes take multiple samples to reduce the chance of undergrading.
Reading Your Pathology Report
On a pathology report, you may see the grade listed as a Roman or Arabic numeral (Grade I, Grade 2), a descriptive term (well-differentiated, moderately differentiated, poorly differentiated), or a cancer-specific score like a Gleason score. Some reports also include the notation “GX,” which means the grade could not be determined from the sample provided. If you see descriptive language, “well-differentiated” aligns with grade I, “moderately differentiated” with grade II, “poorly differentiated” with grade III, and “undifferentiated” or “anaplastic” with grade IV.
The grading system used on your report depends on the type of cancer. Breast, prostate, brain, and liver cancers each have their own established systems, so a “grade 2” in one cancer type doesn’t necessarily carry the same implications as a “grade 2” in another. The grade is most meaningful when interpreted alongside the rest of the pathology report and the full clinical picture.